Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101801 | 0.86 | MRGPRX4 (0.48) | MAPTTDP1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL10107529 | 0.85 | LMNA (0.46) | MAPTSMN1; SMN2CYP2C9CYP2C19TSHR | |
| SCHEMBL10101771 | 0.84 | MAPT (0.42) | MAPTTDP1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL10101770 | 0.84 | MAPT (0.42) | MAPTTDP1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL1534081 | 0.83 | CTSV (0.48) | MAPTTDP1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL10101772 | 0.82 | MAPT (0.40) | MAPTTDP1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL112286 | 0.79 | P4HTM (0.44) | MAPTTDP1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL9287256 | 0.79 | PDE4A (0.51) | MAPTSMN1; SMN2MRGPRX4ALDH1A1RXRA | |
| SCHEMBL9279944 | 0.78 | NPC1 (0.44) | SMN1; SMN2MRGPRX4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL15813873 | 0.78 | MAPT (0.45) | MAPTTDP1L3MBTL1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130345178-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2427190-B1 | 8-AZA TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| EP-2427190-A1 | 8-AZA TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129055-A1 | 8-AZA TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345178-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | MAPT 871/4885TDP1 668/4885L3MBTL1 4744/4885 |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | MAPT 921/4885TDP1 745/4885L3MBTL1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.